Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug Candidate

Novelty Nobility, a clinical-stage biotech company based in South Korea, has expanded its manufacturing agreement with AGC Biologics to advance its bispecific antibody drug candidate, NN4101. The project involves process development and GMP manufacturing at AGC Biologics' facility in Chiba, Japan. AGC Biologics completed cell line development in Copenhagen, Denmark, and is now set for a seamless tech transfer to the Chiba site. NN4101 is a first-in-class bispecific antibody for treating neovascular retinal diseases, combining a fully human anti-c-Kit monoclonal antibody with a vascular endothelial growth factor (VEGF) trap. AGC Biologics is expanding its footprint in Japan with a new state-of-the-art facility in Yokohama.